ProCE Banner Activity

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC

Slideset Download
Conference Coverage
Early results from this phase I trial indicate a manageable safety profile along with robust, durable activity with pembrolizumab + ipilimumab in previously treated patients with advanced NSCLC.

Released: June 02, 2015

Expiration: May 31, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation